Preventing and Managing Cytomegalovirus in High-Risk Hematopoietic Cell Transplantation Patients: Interactive Case Challenge
  • CME

In this Interactive Case Challenge, explore important considerations in CMV prophylaxis and treatment in patients who have undergone hematopoietic cell transplantation.
Roy F. Chemaly, MD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Released: February 26, 2019 Expiration: February 25, 2020

CCO's Interactive Case Challenges guide you through a clinical scenario where the case unfolds according to your choices. If you make a management decision that the faculty member considers to be suboptimal, you'll see the consequences of that choice and be able to mitigate it, before revisiting the questionable decision. Each case ends with a recap of the key learning points and a summary of studies and guidelines that underpin the faculty recommendations.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Formulate prophylactic strategies for patients at high risk for CMV infection following HCT
  • Devise management strategies for HCT patients with CMV infection based on the results of recent clinical studies
  • Provide insightful counsel to patients and colleagues regarding emerging strategies in identifying and managing patients at high risk for CMV infection post HCT

Acknowledgements

Provided by Postgraduate Institute for Medicine.
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

Supported by an educational grant from
Merck & Co., Inc.

Information on this Educational Activity

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Roy F. Chemaly, MD

Professor of Medicine
Department of Infectious Diseases, Infection Control, and Employee Health
The University of Texas MD Anderson Cancer Center
Houston, Texas

Roy F. Chemaly, MD, has disclosed that he has received consulting fees from Chimerix, Clinigen, Merck, Oxford Immunotec, and Shire; fees for non-CME/CE services from Merck and Oxford Immunotec; and funds for research support from Chimerix, Merck, Novartis, Oxford Immunotec, and Shire.

Staff

Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no real or apparent conflicts of interest to report.
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has real or apparent conflicts of interest to report.
Anna Poppa

Editorial Contributor

Anna Poppa has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

The PIM planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for hematologic oncologists and other clinicians practicing within BMT centers.

Goal

The goal of this activity is to close the knowledge and practice gaps and improve clinician competence in managing CMV in patients.

Physician Continuing Medical Education

Joint Accreditation Statement
In support of improving patient care, Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 26, 2019, through February 25, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Download this PDF resource for patients with advanced NSCLC receiving immune checkpoint inhibitor therapy, including information on what to expect and how to actively participate in their care.

Released: December 12, 2019

Interactive algorithm tool providing NCCN Guidelines® recommendations for Management of Immune Checkpoint Inhibitor–Related Toxicities, from CCO

Released: November 5, 2019

Downloadable slides with expert guidance on team approaches for optimal management of patients with chronic myeloid leukemia (CML).

Jorge Cortes, MD Jenny Dahl, PA person default Caitlin R. Rausch, PharmD Released: October 18, 2019

From Clinical Care Options, review this case-based expert commentary on clinical considerations for CAR T-cell therapy in patients with lymphoma

person default Stephen J. Schuster, MD Released: October 17, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?